tTG IgG

When you get screened for celiac disease, the lab almost always runs a different antibody first. That standard test works well for most people, but it quietly fails in the roughly 1 in 500 who are missing a common immune protein in their blood, a gap that shows up more often among people who turn out to have celiac disease.

This is the antibody that steps in when that happens. For someone who lacks that protein, it is one of the most reliable blood signals of whether gluten is damaging their gut.

What This Antibody Actually Reflects

tTG IgG (immunoglobulin G antibodies against tissue transglutaminase) is an autoantibody, meaning your immune system has mistakenly built it against one of your own proteins. The target is an enzyme in your gut called tissue transglutaminase, which normally helps knit proteins together and also modifies gluten fragments.

In celiac disease, gluten fragments latch onto this enzyme and form a combination your immune system treats as foreign. That triggers B cells in the gut lining to produce antibodies, including this IgG form. A high level signals active, gluten-driven inflammation, not just a food sensitivity.

The test measures the concentration of these antibodies in your blood. It does not directly measure gut damage. For the more common IgA version, higher levels track with more severe injury to the intestinal lining; this relationship is less clear for the IgG form, where at least one study found no such correlation. Even so, a strongly positive result usually reflects real underlying disease.

Celiac Disease When You Lack IgA

The routine celiac screen relies on the IgA version of this antibody plus a check of your total IgA. If your body makes little or no IgA, a condition that is more common in people with celiac disease than in the general population, the standard IgA-based test can read falsely reassuring.

This is where the IgG form earns its place. In a study of 325 people that focused on those lacking IgA, the IgG anti-tissue-transglutaminase test correctly flagged nearly all true celiac cases and correctly cleared nearly all people without it (about 99 out of 100 either way). In IgA-deficient adults, it is one of the recommended markers, used alongside IgG antibodies against deamidated gliadin peptide, which guidelines treat as an equivalent or sometimes preferred option.

What this means for you: if you already know you have low or absent IgA, this is one of the celiac antibodies worth ordering. A negative IgA-based screen tells you almost nothing in that situation.

Why It Is Weaker in People With Normal IgA

In people who make IgA normally, this IgG antibody is the junior partner. Across mixed populations, its ability to catch true cases runs around 69 to 72 percent, meaning it misses roughly 3 in 10, while the IgA version catches closer to 9 in 10.

The trade-off is that when it is positive, it tends to be quite specific, correctly staying negative in 94 to 100 percent of people who do not have celiac disease. So a positive result carries weight, but a negative one does not rule celiac disease out if you produce IgA normally.

This is why it is rarely used alone. It is most powerful in confirmed IgA deficiency, or as one piece of a combination panel rather than a standalone screen.

Signals During Pregnancy and Early Life

Some of the most striking outcome data come from studies of the IgA version of this antibody, a related but different measurement, so read these as context rather than direct evidence about the IgG form.

In a pregnancy cohort of about 7,000 women, those with clearly positive anti-tissue-transglutaminase levels had babies weighing about 159 grams less at birth on average than women who tested negative, an association that held after accounting for factors like body weight, smoking, and celiac-linked genes. In a separate cohort of 1,768 pregnant women, being positive was tied to roughly 2.9 times the odds of a low placenta-to-birthweight ratio and about 2.3 times the odds of poor infant weight gain in late infancy.

The common thread is that unrecognized celiac autoimmunity in a mother can shadow early-life growth. Finding and treating it matters beyond digestive symptoms.

A Possible Link to Longer-Term Risk

A general-population study followed 4,633 adults for roughly 8 to 9 years and measured the IgA version of this antibody, again a related but different test than the IgG form.

People with elevated levels had higher death rates over follow-up. Women who tested positive were nearly 4 times as likely to die from any cause (age-adjusted hazard ratio 3.92), and cancer deaths were also elevated in both sexes. These estimates were only adjusted for age, not for lifestyle or other conditions, so some of the effect may reflect other factors, and the same has not been shown for the IgG antibody specifically.

The takeaway is not alarm. It is that celiac autoimmunity is a whole-body condition worth catching, not just a reason to skip bread.

Why One Reading Is Not the Whole Story

A single value is most trustworthy when it is strongly positive on a validated assay in someone with real suspicion of celiac disease. Near the cutoff, it is a different picture.

Repeat measurements of the IgA version taken close together have varied by roughly a factor of two, reflecting real short-term biological and lab variability. Different commercial kits also disagree, with some missing up to a quarter of biopsy-proven cases at standard cutoffs. This is why borderline results deserve a repeat, ideally on the same assay, before any big decision.

Tracking the trend also tells you whether treatment is working. Once someone with celiac disease removes gluten, antibody levels fall over months. In one pediatric study, about half of children saw their tissue transglutaminase antibodies return to normal within 12 months, with higher starting levels taking longer. A reasonable rhythm is a baseline, a recheck at 3 to 6 months after starting a gluten-free diet, then at least once a year.

One important limit: normalized antibodies do not guarantee a healed gut. A meta-analysis found that tissue transglutaminase and related antibody tests miss most people who still have intestinal damage while on a gluten-free diet. A normal number is encouraging but not proof of full recovery.

When Results Can Be Misleading

A few situations can push this antibody up or make a single reading hard to interpret:

• Assay differences: the same blood sample can produce different numbers on different lab platforms, and the cutoff for positive varies by kit, so results are hard to compare across labs.
• Other conditions: elevated tissue transglutaminase antibodies have been reported in chronic liver disease, diabetes, some arthritis and inflammatory conditions, and in nearly half (about 48 percent) of people with end-stage heart failure, none of which is celiac disease. A positive result outside the right clinical context needs confirmation.
• A gluten-free diet before testing: if you have already cut gluten, antibody levels drop and can normalize even when the gut is not fully healed, producing a falsely reassuring result. Testing is most meaningful while you are still eating gluten.

Common metabolic medications, acute illness, surgery, exercise, and what you ate in the day or two before the draw have not been shown to meaningfully shift this antibody. Unlike many blood markers, it reflects sustained immune activity over weeks, not short-term fluctuations, so you do not need to fast or change your routine before testing.

What to Do With an Unexpected Result

A positive result is a starting point, not a diagnosis. The next moves depend on the pattern of findings rather than any single number.

• Confirm your IgA status: if you have not already, check total IgA. This tells you whether the IgG test was even the right one to rely on and whether the IgA-based tests are trustworthy for you.
• Add companion antibodies: endomysial antibodies and deamidated gliadin peptide IgG can sharpen the picture, and a strongly positive combination raises confidence before biopsy.
• Consider genetics and biopsy: HLA-DQ2 and DQ8 typing can help, and a small-bowel biopsy remains the reference standard for confirming celiac disease in most adults.
• Loop in a specialist: a gastroenterologist should confirm the diagnosis before you commit to a lifelong gluten-free diet, since starting the diet first can erase the very signals needed to diagnose you.

If the result is borderline and you feel well, the sensible path is to repeat it on the same assay while still eating gluten, rather than assuming either the best or the worst.